eligibility_summary
Eligible participants must have a clinical diagnosis of cervical squamous cell carcinoma and be HER-2 positive. Those with cervical adenocarcinoma are excluded.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06558682 tests neoadjuvant Disitamab Vedotin plus cisplatin in HER2‑positive locally advanced cervical squamous carcinoma (IB3–IIA2). Disitamab Vedotin (Aidixi, RC48) is an antibody–drug conjugate: a humanized anti‑HER2 IgG1 linked to the microtubule toxin MMAE via a cleavable linker. Mechanism: binds HER2 (ERBB2) on tumor cells, internalizes, releases MMAE to disrupt microtubules, causing mitotic arrest and apoptosis, may exert bystander killing of nearby HER2‑low cells. Cisplatin is a platinum cytotoxic chemotherapy that forms DNA intra/interstrand crosslinks, blocking replication/transcription and inducing apoptosis. Targets/pathways: HER2‑expressing cervical cancer cells, HER2 signaling, tubulin/microtubule dynamics, DNA damage response and cell‑cycle checkpoints, apoptosis. Exploratory aims assess HER2 and immune factor changes/biomarkers.